AZILSARTAN MEDOXOMIL Drug Patent Profile
✉ Email this page to a colleague
When do Azilsartan Medoxomil patents expire, and when can generic versions of Azilsartan Medoxomil launch?
Azilsartan Medoxomil is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in AZILSARTAN MEDOXOMIL is azilsartan kamedoxomil. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the azilsartan kamedoxomil profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AZILSARTAN MEDOXOMIL?
- What are the global sales for AZILSARTAN MEDOXOMIL?
- What is Average Wholesale Price for AZILSARTAN MEDOXOMIL?
Summary for AZILSARTAN MEDOXOMIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 28 |
| Patent Applications: | 261 |
| DailyMed Link: | AZILSARTAN MEDOXOMIL at DailyMed |
Recent Clinical Trials for AZILSARTAN MEDOXOMIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Takeda | |
| Lee's Pharmaceutical Limited | Phase 3 |
| Takeda | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for AZILSARTAN MEDOXOMIL
US Patents and Regulatory Information for AZILSARTAN MEDOXOMIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | AZILSARTAN MEDOXOMIL | azilsartan kamedoxomil | TABLET;ORAL | 214489-001 | Jul 20, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin Ltd | AZILSARTAN MEDOXOMIL | azilsartan kamedoxomil | TABLET;ORAL | 214489-002 | Jul 20, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
